Industry Insights Logo

The Rebate Model Is Just One Item on Your 2027 340B Radar

SPONSORED CONTENT

HRSA’s revised 340B Rebate Model Pilot Program is scheduled to begin January 1, 2027. Ten manufacturers have approved plans covering 18 drugs, including Eliquis, Jardiance, Farxiga, and Januvia. On October 9, the American Hospital Association, the Maine Hospital Association, and four safety-net hospitals asked a federal court in Maine to stop the pilot before it launches.

A year ago, the same court blocked HRSA’s first rebate pilot days before it was set to begin. Many covered entities (CEs) are wondering whether this time will play out the same way.

What HRSA Did Differently This Time

When the court blocked the first pilot, it did not say HRSA lacked the authority to approve a rebate model. It said HRSA had not followed the right process.

It asked for more input. Before relaunching, HRSA published a request for information, responded to more than 2,400 public comments, and took comments on its projections of the pilot’s impact.

It added protections for CEs. Manufacturers must pay or deny rebates within 10 days of a complete submission, pay at the unit level, and cover all platform costs. They cannot deny rebates over eligibility, diversion, or duplicate discount concerns. HRSA also added a formal dispute process, a transition grace period, and a 90-day notice requirement before manufacturer plans take effect.

The courts have clarified the rules. A federal appeals court confirmed this year that only HHS can approve a rebate model. That makes HRSA’s pilot the only path manufacturers have.

The lawsuit is still a serious challenge. The hospital groups argue that HRSA continues to undercount what the pilot will cost them, estimating about $537 million a year in administrative costs where hospital analyses put it above $1 billion, and that it understates the cash flow strain of paying full price up front while waiting on rebates. That is the same kind of issue that stopped the first pilot. Still, HRSA built a much longer record this time, and the bar for blocking the pilot is higher. CEs cannot count on another last-minute pause.

Why We Think Preparing Now Is Important

Our view is simple: plan as if the rebate model starts January 1, 2027.

If the pilot moves forward, programs that waited will be registering for Beacon and mapping claims data in January while already paying WAC for these drugs. If the pilot is blocked, the preparation is not wasted. The same work applies to manufacturer data requirements, Medicare negotiated prices, and the other changes coming in 2027.

What the Rebate Model Covers

Under the pilot, CEs will buy the 18 included drugs at wholesale acquisition cost (WAC) through their existing 340B wholesaler account, submit claims data through the Beacon platform within 45 days of dispense, and receive a rebate once the claim is approved.

Not every negotiated drug is in the rebate model. Ozempic and Wegovy, for example, are not included. The pilot only covers drugs whose manufacturers received approved rebate plans.

On the 2027 negotiated price list, but not in the rebate model:

  • Ozempic
  • Wegovy
  • Rybelsus
  • Calquence

Medicare Part D will reimburse these drugs at the lower negotiated rate, but you will continue to buy them at the upfront 340B price.

Leaving the negotiated price list in 2027:

  • Entresto
  • Xarelto
  • Stelara
  • NovoLog / Fiasp

Generic or biosimilar competition removes these drugs from Medicare negotiation on January 1, 2027. They are not in the rebate model either, so upfront 340B purchasing continues.

What We Learned in 2026

When the first pilot was blocked, many programs assumed nothing would change. The opposite happened. In January, Medicare negotiated prices took effect for the first 10 Part D drugs, capping reimbursement at the negotiated price plus a dispensing fee. Because 340B savings come from the gap between reimbursement and the 340B price, savings on these drugs dropped, often before anyone noticed. Over the rest of the year, many manufacturers expanded their in-house pharmacy and medical claims data requirements, and some programs lost 340B pricing for falling behind.

The rebate model was paused. Everything around it kept moving.

What Else Is on the Radar for 2027

More Medicare negotiated prices. Fifteen more drugs get negotiated prices on January 1, 2027. Some, like Trelegy Ellipta, Xtandi, Janumet, and Tradjenta, are also in the rebate model. Expect reimbursement pressure on a longer list of drugs.

Part B drugs are next. The next round of negotiated prices, expected this fall and effective in 2028, includes physician-administered drugs for the first time. Hospitals with infusion centers should start planning now.

More manufacturer data requirements. Claims data requirements keep expanding to more products and settings, with more consequences for missed deadlines and more denials to catch, correct, and resubmit.

More state rules, in more states. More than 20 states have passed laws protecting contract pharmacy arrangements, and a growing number, including Minnesota and Illinois, now require CEs to report 340B data on a set schedule. A growing number of states also have laws that protect against drug industry claims data reporting requirements. Each law brings its own deadlines, definitions, and workflows.

A changing federal picture. Congress is weighing competing 340B reform bills, and the administration has proposed moving program oversight from HRSA to CMS. Neither is likely to change things before January, but either could reshape audits and reporting.

Why 340B Needs a Team

For many cash-strapped 340B providers, 340B operations are still overseen by one person or a very small group. That worked when the program was mostly about purchasing and eligibility. It does not work when 340B touches rebates, reimbursement, data submissions, state law, and federal policy all at once. A program ready for 2027 has a clear owner for pharmacy operations, finance, compliance, data and claims, and leadership. These do not all need to be full-time roles, but each needs an owner, and those owners need to talk to each other.

How to Prepare Now

1. Map who owns what today. List every 340B responsibility and the person who handles it. Gaps and single points of failure show up quickly.

2. Know your exposure. Review what the 2026 negotiated drugs did to your savings, then pull purchase data for the 18 rebate pilot drugs and the 2027 negotiated list.

3. Get ready for Beacon. Gather your registration documents and confirm you can produce the required pharmacy and medical claims data fields. If your TPA submits for you, confirm who handles denials and reconciliation.

4. Inventory every requirement. List each manufacturer data requirement, state law, and reporting deadline that applies to you, with an owner next to each one.

5. Automate what you can. Manual spreadsheets and one-off uploads do not scale across multiple platforms, states, and deadlines.

How RxTrail Handles It

We work as an extension of your team. Our software automates claims submissions and tracks manufacturer and state requirements in one place. Our consultants cover compliance, financial analysis, and denial management, and for programs short on staff, we can provide the people to run it. Your team keeps decision-making and patient care. We fill the gaps.

Ready for 2027

HRSA learned from its first attempt, and this version of the rebate model is more likely to hold up, but the court will have the final word. Plan for it to start on January 1, and plan for everything else coming with it, from Washington and from your state capitol. If you want help understanding your exposure and building the right team around your program, reach out to RxTrail.

Lindsey Martin is VP of Consulting at RxTrail. She can be reached at lmartin@rxtrail.org

Website | + posts

Read more 340B Expert Tips

LinkedIn

Site Footer Live